Trexquant Investment LP Allogene Therapeutics, Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$4.53 - $6.74 $167,265 - $248,867	-36,924 Reduced 42.31%	50,336 $250,000
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $121,155 - $202,171	-24,625 Reduced 22.01%	87,260 $431,000
Q4 2022 Feb 13, 2023	BUY	$5.62 - $11.11 $628,793 - $1.24 Million	111,885 New	111,885 $703,000
Q2 2022 Aug 11, 2022	BUY	$6.78 - $12.28 $100,703 - $182,394	14,853 New	14,853 $169,000
Q3 2021 Nov 12, 2021	SELL	$21.01 - $27.64 $510,984 - $672,232	-24,321 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$23.49 - $35.8 $571,300 - $870,691	24,321 New	24,321 $634,000
Q4 2020 Feb 11, 2021	SELL	$25.24 - $43.45 $282,864 - $486,944	-11,207 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$32.38 - $44.96 $131,883 - $183,122	-4,073 Reduced 26.66%	11,207 $423,000
Q2 2020 Aug 07, 2020	SELL	$18.39 - $54.04 $224,376 - $659,342	-12,201 Reduced 44.4%	15,280 $654,000
Q1 2020 May 08, 2020	BUY	$18.22 - $28.25 $244,530 - $379,143	13,421 Added 95.46%	27,481 $534,000
Q4 2019 Feb 12, 2020	BUY	$24.82 - $31.4 $348,969 - $441,484	14,060 New	14,060 $365,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.